Visualizing beta cells in patients with a history of gestational diabetes.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520392-27-00

Enrollment

Registered

2025-01-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes

Brief summary

The main parameter of the study is the quantitative assessment of pancreatic 68Ga-NODAGA-exendin-4 uptake women with and without a history of GDM by PET/CT.

Detailed description

The correlation between Ga-exendin tracer accumulation and beta cell function of the subjects

Interventions

DRUGEXENATIDE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Secondary

Measure	Time frame
The correlation between Ga-exendin tracer accumulation and beta cell function of the subjects	—

Primary

Measure	Time frame
The main parameter of the study is the quantitative assessment of pancreatic 68Ga-NODAGA-exendin-4 uptake women with and without a history of GDM by PET/CT.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026